参考文献/References:
[1] Maron BJ,Rowin EJ,Maron MS. Global burden of hypertrophic?cardiomyopathy[J]. JACC Heart Fail,2018,6(5):376-378.
[2] 中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组,中华心血管病杂志编辑委员会. 中国成人肥厚型心肌病诊断与治疗指南[J]. 中华心血管病杂志,2017,45(12):1015-1032.
[3] Elliott PM,Anastasakis A,Borger MA,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
[4] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.
[5] Wang W,Jiang B,Sun H,et al. Prevalence,incidence,and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults[J]. Circulation,2017,135(8):759-771.
[6] 编写组中国脑卒中防治报告. 我国脑卒中防治仍面临巨大挑战——《中国脑卒中防治报告2018》概要[J]. 中国循环杂志,2019,34(2):105-119.
[7] Haruki S,Minami Y,Hagiwara N. Stroke and embolic events in hypertrophic cardiomyopathy:risk stratification in patients without atrial fibrillation[J]. Stroke,2016,47(4):936-942.
[8] Guttmann OP,Pavlou M,O’Mahony C,et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy(HCM Risk-CVA)[J]. Eur J Heart Fail,2015,17(8):837-845.
[9] Takayoshi H,Toru K,Yuichi B,et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort―results from Kochi RYOMA study[J]. Circ J,2019,83(8):1747-1754.
[10] 国家卫生健康委员会脑卒中防治专家委员会房颤卒中防治专业委员会,中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 中国心源性卒中防治指南(2019)[J]. 中华心律失常学杂志,2019,23(6):463-484.
[11] Jame S,Barnes G. Stroke and thromboembolism prevention in atrial fibrillation[J]. Heart,2020,106(1):10-17.
[12] Guttmann OP,Rahman MS,O’Mahony C,et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review[J]. Heart,2014,100(6):465-472.
[13] Tsuda T,Hayashi K,Fujino N,et al. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation[J]. Heart Rhythm,2019,16(6):829-837.
[14] Watson T,Shantsila E,Lip GY. Mechanisms of thrombogenesis in atrial fibrillation:Virchow’s triad revisited[J]. Lancet,2009,373(9658):155-166.
[15] Philipson DJ,Rader F,Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy[J]. Eur J Prev Cardiol,2019,Feb 6;2047487319828474.
[16] Yakar TS,Kayikcioglu M,Tuluce K,et al. Assessment of left atrial appendage function during sinus rhythm in patients with hypertrophic cardiomyopathy:transesophageal echocardiography and tissue Doppler study[J]. J Am Soc Echocardiogr,2010,23(11):1207-1216.
[17] Sivalokanathan S,Zghaib T,Greenland GV,et al. Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging[J]. JACC Clin Electrophysiol,2019,5(3):364-375.
[18] Yang C,Zhang C,Yuan J,et al. Prevalence and determinants of elevated D-dimer in patients with hypertrophic cardiomyopathy[J]. Biomark Med,2020,14(2):131-140.
[19] Cambronero F,Vilchez JA,García-Honrubia A,et al. Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy[J]. Thromb Res,2010,126(1):e46-e50.
[20] Borer J,Atar D,Marciniak T,et al. Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy:important new insights[J]. Thromb Haemost,2019,119(3):355-357.
[21] Dimitrow PP,Undas A,Bober M,et al. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation[J]. Heart,2008,94(6):e21.
[22] Khan AA,Lip GYH. The prothrombotic state in atrial fibrillation:pathophysiological and management implications[J]. Cardiovasc Res,2019,115(1):31-45.
[23] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy[J]. Circulation,2020,142(25):e533-e557.
[24] Lin T,Sung Y,Ko T,et al. Risk of ischemic stroke in patients with hypertrophic cardiomyopathy in the absence of atrial fibrillation—a nationwide cohort study[J]. Aging,2019,11(23):11347-11357.
[25] Minami Y,Haruki S,Yashiro B,et al. Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation[J]. J Cardiol,2016,68(6):478-484.
[26] Debonnaire P,Joyce E,Hiemstra Y,et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation[J]. Circ Arrhythm Electrophysiol,2017,10(2):e004052.
[27] Paraskevaidis IA,Farmakis D,Papadopoulos C,et al. Two-dimensional strain analysis in patients with hypertrophic cardiomyopathy and normal systolic function:a 12-month follow-up study[J]. Am Heart J,2009,158(3):444-450.
[28] Wai SH,Kyu K,Galupo MJ,et al. Assessment of left atrial appendage function by transthoracic pulsed Doppler echocardiography:comparing against transesophageal interrogation and predicting echocardiographic risk factors for stroke[J]. Echocardiography,2017,34(10):1478-1485.
[29] Sasaki S,Watanabe T,Tamura H,et al. Left atrial strain as evaluated by two-dimensional speckle tracking predicts left atrial appendage dysfunction in patients with acute ischemic stroke[J]. BBA Clin,2014,2:40-47.
[30] Akoum N,Fernandez G,Wilson B,et al. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation[J]. J Cardiovasc Electrophysiol,2013,24(10):1104-1109.
[31] Meschia JF,Bushnell C,Boden-Albala B,et al. Guidelines for the primary prevention of stroke:a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke,2014,45(12):3754-3832.
[32] He S,Wang Z,Cheem TH,et al. External validation of the model of thromboembolic risk in hypertrophic cardiomyopathy patients[J]. Can J Cardiol,2019,35(12):1800-1806.
[33] Maron BJ,Olivotto I,Bellone P,et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2002,39(2):301-307.
[34] Kaptoge S,di Angelantonio E,Lowe G,et al. C-reactive protein concentration and risk of coronary heart disease,stroke,and mortality:an individual participant meta-analysis[J]. Lancet,2010,375(9709):132-140.
[35] Zhu L,Zou Y,Wang Y,et al. Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy[J]. J Am Heart Assoc,2017,6(2):e004529.
[36] H?gye M,Mándi Y,Csanády M,et al. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy[J]. Am J Cardiol,2004,94(2):249-251.
[37] Reineck E,Rolston B,Bragg-Gresham JL,et al. Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy[J]. Am J Cardiol,2013,111(7):1034-1039.
[38] Lu Y,Hajifathalian K,Ezzati M,et al. Metabolic mediators of the effects of body-mass index,overweight,and obesity on coronary heart disease and stroke:a pooled analysis of 97 prospective cohorts with 1.8 million participants[J]. Lancet,2014,383(9921):970-983.
[39] Yang J,Wang L,Sun T,et al. Obesity is associated with worse long-term outcomes in hypertrophic cardiomyopathy patients with acute myocardial infarction[J]. Perfusion,2020,35(5):384-392.
[40] Saberi S,Wheeler M,Bragg-Gresham J,et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy:a randomized clinical trial[J]. JAMA,2017,317(13):1349-1357.
[41] Saberi S,Day SM. Exercise and hypertrophic cardiomyopathy:time for a change of heart[J]. Circulation,2018,137(5):419-421.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(7):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(7):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[7]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[8]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(7):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[9]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(7):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
[10]王蕊 赵鹏军.儿童肥厚型心肌病诊断方法及其对猝死风险评估的价值[J].心血管病学进展,2023,(8):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]
WANG Rui,ZHAO Pengjun.Diagnostic Methods of Hypertrophic Cardiomyopathy in Children and Its Value in Risk Assessment of Sudden Death[J].Advances in Cardiovascular Diseases,2023,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]